MedPath

Effects of Therapeutic Exercise in Patients With Fibromyalgia

Not Applicable
Completed
Conditions
Chronic Pain
Therapeutic Exercise
Interventions
Other: Therapeutic Exercise
Registration Number
NCT04817605
Lead Sponsor
Universidad de Zaragoza
Brief Summary

Fibromyalgia syndrome is characterized by chronic generalized musculoskeletal pain associated with fatigue, sleep disturbances and some biochemical markers. The European League Againts Rheumatism (EULAR) described an algorithm how to treat step by step these patients.

The objective of this trial is to evaluate if therapeutic exercise is effective on fatigue, pain threshold, quality of life, quality of sleep, pain coping and biochemical and genetic markers.

For this purpose, the investigators conduct a randomized controlled trial double-blind (patient and examiner). The investigators included patients diagnosed of fibromyalgia according to the American College of Rheumatology (ACR).

Patients included one group receiving exercise therapy consisting of 3 treatment sessions a week over 10 weeks.

The variables are measured at the beginning and end of treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
30
Inclusion Criteria
  • Diagnosed medically with Fibromyalgia
  • Diagnosed according to the American College of Rheumatology criteria
  • Agreement to attend to treatment sessions
Exclusion Criteria
  • Any kind of contraindications for physical activity
  • Other kind of diseases that could limit the intervention
  • Previous surgery last year
  • Medication modifications in the last 3 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Exercise TherapyTherapeutic Exercise-
Primary Outcome Measures
NameTimeMethod
Quality of Sleepthrough study completion, an average 10 weeks

The investigators measure the quality of sleep with Pittsburg Sleeping Questionnaire Index (PSQI) at baseline

Pain intensitythrough study completion, an average 10 weeks

VAS

Secondary Outcome Measures
NameTimeMethod
Analysis of tryptophan metabolitesthrough study completion, an average 10 weeks

The investigators measure the tryptophan metabolites with blood test analysis at baseline

Pressure pain thresholdthrough study completion, an average 10 weeks

The investigators measure the pressure pain threshold of the 18 points described initially by the American College of rheumatology with a digital algometer at the end of treatment

Central sensitizationthrough study completion, an average 10 weeks

The investigators measure the central sensitization with Chronic Pain Self-Efficacy Scale (CPSS)

Trial Locations

Locations (1)

Sandra Jiménez Jiménez-del-Barrio

🇪🇸

Soria, Spain

© Copyright 2025. All Rights Reserved by MedPath